CA2369454A1 - Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes - Google Patents

Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes Download PDF

Info

Publication number
CA2369454A1
CA2369454A1 CA002369454A CA2369454A CA2369454A1 CA 2369454 A1 CA2369454 A1 CA 2369454A1 CA 002369454 A CA002369454 A CA 002369454A CA 2369454 A CA2369454 A CA 2369454A CA 2369454 A1 CA2369454 A1 CA 2369454A1
Authority
CA
Canada
Prior art keywords
mammalian
tissue
protein
antagonist
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369454A
Other languages
English (en)
Inventor
Robert M. Hoek
Jonathan D. Sedgwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369454A1 publication Critical patent/CA2369454A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

On décrit des compositions et des procédés dans lesquels on utilise un ligand OX2 de mammifère pour traiter une condition pathologique anormale chez un individu. Les procédés consistent à administrer une quantité thérapeutiquement efficace de OX2 seul ou bien en combinaison avec d'autres réactifs thérapeutiques; ou un antagoniste OX2.
CA002369454A 1999-04-13 2000-04-12 Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes Abandoned CA2369454A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29082599A 1999-04-13 1999-04-13
US09/290,825 1999-04-13
PCT/US2000/009719 WO2000061171A2 (fr) 1999-04-13 2000-04-12 Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes

Publications (1)

Publication Number Publication Date
CA2369454A1 true CA2369454A1 (fr) 2000-10-19

Family

ID=23117713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369454A Abandoned CA2369454A1 (fr) 1999-04-13 2000-04-12 Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes

Country Status (7)

Country Link
EP (1) EP1171154A2 (fr)
JP (1) JP2002541210A (fr)
AR (1) AR023464A1 (fr)
AU (1) AU4341300A (fr)
CA (1) CA2369454A1 (fr)
MX (1) MXPA01010480A (fr)
WO (1) WO2000061171A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003291A (es) 2001-10-12 2004-07-23 Schering Corp Uso de anticuerpos biespecificos para ragular respuestas inmunes.
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
GB202115803D0 (en) 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
WO2023214388A1 (fr) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Nouvelles protéines de fusion cd200
WO2023214387A1 (fr) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Nouvelles protéines de fusion cd200

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
AU1144097A (en) * 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
ATE319825T1 (de) * 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation

Also Published As

Publication number Publication date
WO2000061171A9 (fr) 2002-01-03
JP2002541210A (ja) 2002-12-03
WO2000061171A3 (fr) 2001-01-25
AU4341300A (en) 2000-11-14
WO2000061171A2 (fr) 2000-10-19
AR023464A1 (es) 2002-09-04
EP1171154A2 (fr) 2002-01-16
MXPA01010480A (es) 2002-03-27

Similar Documents

Publication Publication Date Title
US20020192215A1 (en) Novel uses of mammalian OX2 protein and related reagents
ES2149149T3 (es) Proteinas de union a interleuquina-18, su preparacion y uso.
Girard et al. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC
US20120141456A1 (en) Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System
EP1121454A1 (fr) Nouvelle proteine extracellulaire liant le peptide rage (en-rage), et utilisations correspondantes
US6555340B1 (en) Nucleic acid encoding bovine extracellular rage binding protein (en-rage)
WO2007098283A2 (fr) Utilisation d'antagonistes de molécules complexes du récepteur maif (macrophage migration-inhibitory factors) et de facteurs neurotrophiques pour traiter des maladies et des troubles neurologiques
EP1326974B1 (fr) Procedes relatifs a l'utilisation de polypeptide lie a l'interleukine 17 (il-17) humaine pour le traitement de maladies-
WO1994017184A1 (fr) Modulation de la reponse physiologique de lymphocytes par les molecules cd38 ou leurs anti-corps
JP2007319163A (ja) Ｏｘ２レセプターホモログ
US20020138860A1 (en) Novel uses of mammalian CCR6 receptors and related reagents
US20030215442A1 (en) Methods and compositions for the treatment or prevention of immune disorders using combination therapy
NZ238659A (en) Mast cell growth factor, recombinant production and isolated sequences
CA2369454A1 (fr) Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes
US20150329638A1 (en) Use of DR6 Antagonists to Improve Motor Neuron Disease
CA2235951C (fr) Nouveaux emplois du ctla-8 de mammifere et reactifs associes
KR20000075732A (ko) 임파구의 활성화 억제제
JP4482235B2 (ja) 哺乳動物ランゲルハンス細胞抗原に対する抗体およびそれらの使用
Hasegawa et al. Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation
AU705281B2 (en) Secreted human fas antigen
WO1996020206A9 (fr) Antigene du fas secrete par l'homme
US6063372A (en) Uses of mammalian CTLA-8 and related reagents
WO1995002611A1 (fr) Proteine de surface cellulaire presente sur les cellules tueuses naturelles appelee dx1
US20060165689A1 (en) Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
Sytwu T cell activation, apoptosis, and autoimmune disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead